Cognition Therapeutics (CGTX) Return on Capital Employed (2021 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Return on Capital Employed of 118.31% for Q1 2026, up 21869.0% year-over-year from N/an in Q1 2025, and up 20.88% quarter-over-quarter from 149.52% in Q4 2025.
Cognition Therapeutics (CGTX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Return on Capital Employed for 6 consecutive years, with 118.31% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 21869.0% year-over-year to 118.31%; the TTM figure through Mar 2026 stood at 118.31% (up 21869.0% YoY), while the FY2025 annual figure was 188.27%, up 6207.0% from the prior year.
- Return on Capital Employed rose to 118.31% in Q1 2026 per CGTX's latest filing, from 149.52% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 54.48% in Q1 2022 and bottomed at 575.61% in Q2 2025.
- Historically, Return on Capital Employed has averaged 190.87% across 5 years, with a median of 149.52% in 2025.
- Annual changes were most pronounced in 2025 — Return on Capital Employed plunged 34706 bps — and 2026, when it soared 21869 bps.
- Cognition Therapeutics' Return on Capital Employed stood at 82.38% in 2022, then slumped by 130 bps to 189.28% in 2023, then slumped by 60 bps to 303.79% in 2024, then soared by 51 bps to 149.52% in 2025, then increased by 21 bps to 118.31% in 2026.
- Business Quant data shows CGTX's Return on Capital Employed at 118.31% in Q1 2026, 149.52% in Q4 2025, and 180.45% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | -114.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -114.14% |
| Mar 31, 2026 | -118.31% |
| Dec 31, 2025 | -149.52% |
| Sep 30, 2025 | -180.45% |
| Jun 30, 2025 | -575.61% |
| Mar 31, 2025 | -336.99% |
| Dec 31, 2024 | -303.79% |
| Sep 30, 2024 | -319.84% |
| Jun 30, 2024 | -228.55% |
| Mar 31, 2024 | -203.07% |
| Dec 31, 2023 | -189.28% |
| Sep 30, 2023 | -144.09% |
| Jun 30, 2023 | -123.66% |
| Mar 31, 2023 | -88.64% |
| Dec 31, 2022 | -82.38% |
| Sep 30, 2022 | -87.67% |
| Jun 30, 2022 | -58.45% |
| Mar 31, 2022 | -54.48% |
| Dec 31, 2021 | -64.43% |